Audentes Therapeutics (NASDAQ:BOLD) issued its earnings results on Tuesday. The biotechnology company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.09), Briefing.com reports. During the same period last year, the business earned ($0.88) earnings per share.
NASDAQ:BOLD traded down $5.33 during mid-day trading on Wednesday, reaching $24.23. 3,418,753 shares of the stock were exchanged, compared to its average volume of 443,136. The company has a market capitalization of $1.10 billion, a PE ratio of -7.13 and a beta of 1.99. Audentes Therapeutics has a 1 year low of $19.62 and a 1 year high of $46.18.
In related news, CEO Matthew R. Patterson sold 21,000 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $38.16, for a total transaction of $801,360.00. Following the transaction, the chief executive officer now owns 17,144 shares in the company, valued at approximately $654,215.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Suyash Prasad sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $36.88, for a total value of $368,800.00. Following the transaction, the vice president now owns 100 shares in the company, valued at approximately $3,688. The disclosure for this sale can be found here. Insiders have sold a total of 77,039 shares of company stock worth $2,925,260 in the last 90 days. 6.60% of the stock is currently owned by company insiders.
BOLD has been the topic of several research analyst reports. Zacks Investment Research raised Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a research report on Tuesday, July 10th. HC Wainwright set a $40.00 target price on Audentes Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 22nd. Mizuho reissued a “buy” rating and set a $45.00 target price on shares of Audentes Therapeutics in a research report on Wednesday, August 22nd. William Blair reissued a “buy” rating on shares of Audentes Therapeutics in a research report on Tuesday, August 7th. Finally, BidaskClub raised Audentes Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, September 18th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $36.00.
COPYRIGHT VIOLATION NOTICE: “Audentes Therapeutics (BOLD) Posts Quarterly Earnings Results, Misses Expectations By $0.09 EPS” was first posted by Week Herald and is the property of of Week Herald. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://weekherald.com/2018/11/07/audentes-therapeutics-bold-posts-quarterly-earnings-results-misses-expectations-by-0-09-eps.html.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.